...SVP, preclinical and translational science. Bond was most recently VP of cellular engineering at Kite Pharma. Karuna...

...chemogenetic platforms, and three others —Limbix, Karuna...
...Rules of the Road”). Both Limbix and Karuna...
...is focusing on depression in adolescents and Karuna...

...a radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer. Karuna discontinues KarXT for pain Karuna...
...plus trospium chloride, xanomeline plus trospium chloride RXC006 Qinlock ripretinib (DCC-2618) fasinumab (MT-5547, REGN475, SAR164877) DBV Technologies S.A. Point Biopharma Inc. Karuna...

...Gilead (see "Gilead to Seek Pause in HIV PrEP Suit" ). PureTech sells $200M of Karuna...
...Karuna Therapeutics Inc. (NASDAQ:KRTX), leaving PureTech with a 20.4% stake in the biotech. In November, Karuna...
...emtricitabine/tenofovir Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Gilead Sciences Inc. Roche Karuna Pharmaceuticals Inc. PureTech...

...Program” ). Data readouts also drove big stock gains during 4Q19 for companies such as Karuna...
...Inc. (NASDAQ:KRTX), Myovant Sciences Inc. (NASDAQ:MYOV), Axsome Therapeutics Inc. (NASDAQ:AXSM) and ChemoCentryx Inc. (NASDAQ:CCXI) (see “Karuna...

...stock move reflected continued investor enthusiasm for biotechs with strong clinical data in recent weeks. Karuna...
...more than doubled the next day after revealing Phase III data in prostate cancer (see "Karuna...

...Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate...
...Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna...
...its close Monday when it proposed the offering. Karuna fell $29.58 (27%) to $79.37 Thursday. Karuna...

...avoiding the side effects that dogged a decades-old attempt to modulate the targets. Shares of Karuna...
...$29, just days after its June 2019 IPO. Data from the Phase II study showed Karuna's...
...to read out in mid-2020 (see "Karuna Looks Past Schizophrenia with Series B" ). Following Karuna's...

...not cite a reason for the move. Karuna Labs raises seed round Digital health company Karuna...
...joined by Anorak Ventures, the AET Fund, the Hustle Fund, Correlation Ventures and Dreamit Ventures. Karuna...

...Pharma Inc. and participated in a $68 million series B crossover round for neurology company Karuna...
...City, Calif. China Medical Systems Holding Ltd. (HKSE:867), Shenzen, China Inozyme Pharma Inc., Boston, Mass. Karuna...